Shots:

• ASPECT-NP study (N=726) assessing ZERBAXA 3g IV (ceftolozane & tazobactam) vs. Meropenem 1g IV every eight hrs. for 8 to 14 days/ 14 days for Pseudomonas aeruginosa infection
• ASPECT-NP resulted in affinity of ZERBAXA for treating HABP and VABP in patients- which will further help in filling sNDA to the US and EMA seeking its approval for HABP and VABP
• ZERBAXA 1.5g (ceftolozane 1g and tazobactam 0.5g) is approved in the US for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis in adults

Ref: Merck | Image: Merck